News
-
Apremilast (Otezla®)
Reimbursement not recommended at the submitted price.
-
Lixisenatide (Lyxumia®)
The NCPE does not recommend reimbursement of lixisenatide for patients with type 2 diabetes mellitus at the submitted price.
-
Eltrombopag (Revolade®)
-
Apixaban (Eliquis®)
The NCPE believe that apixaban is cost effective for this indication
-
Pneumococcal Vaccination
Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost-effective option if the analysis is based on a serotype distribution reflecting 2011 data. download document
-
Oncotype DX®
Cost-effectiveness of Oncotype DX® to target chemotherapy use in lymph-node-negative, oestrogen-receptor-positive, early-stage breast cancer in Ireland.
-
Fingolimod (Gilenya®)
Following a price revision we now consider Fingolimod (Gilenya®) a cost-effective therapy for the treatment of relapsing-remitting multiple sclerosis patients in the Irish healthcare setting.
-
Rotavirus Vaccine
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland
-
Colorectal Cancer Screening programme
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.
-
Glucosamine sulfate (Dona®)
We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.